{"id":483180,"date":"2020-05-07T22:26:01","date_gmt":"2020-05-07T22:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483180"},"modified":"2020-05-07T22:26:01","modified_gmt":"2020-05-07T22:26:01","slug":"soft-tissue-sarcoma-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/soft-tissue-sarcoma-pipeline-insight-2020_483180.html","title":{"rendered":"Soft Tissue Sarcoma Pipeline Insight, 2020"},"content":{"rendered":"
\"Soft<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Soft Tissue Sarcoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease overview and Soft Tissue Sarcoma treatment guidelines.<\/div>\n

“<\/span>Soft Tissue Sarcoma Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the <\/span>Soft Tissue Sarcoma <\/span>market. A detailed picture of the <\/span>Soft Tissue Sarcoma <\/span>pipeline landscape is provided, which includes the disease overview and <\/span>Soft Tissue Sarcoma <\/span>treatment guidelines. <\/span><\/p>\n

The assessment part of the report embraces in-depth <\/span>Soft Tissue Sarcoma <\/span>commercial assessment and clinical assessment of the <\/span>Soft Tissue Sarcoma <\/span>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <\/span>Soft Tissue Sarcoma <\/span>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/span><\/p>\n

\"\"<\/strong><\/p>\n

The launch of the emerging therapies is expected to significantly impact Soft Tissue Sarcoma treatment scenario in the upcoming years:-<\/strong><\/p>\n

Drugs covered<\/strong>
1. Avapritinib (BLU-285)<\/span>
2. Anlotinib (AL3818)<\/span>
3. Selinexor<\/span>
4. Aldoxorubicin (INNO-206)<\/span>
5. Ripretinib (DCC-2618)<\/span>
6. Fibromun (In combination with Doxorubicin)<\/span>
7. Hensify (NBTXR3)<\/span>
8. Crenolanib<\/span>
9. TAS-116<\/span>
10. GSK3377794<\/span>
11. ADP-A2M4<\/span>
12. Tazemetostat (EPZ-6438)<\/span>
13. AMG 337<\/span>
14. GB226\/APL-501<\/span>
15. Camsirubicin<\/span>
And many others<\/span><\/p>\n

The key players in Soft Tissue Sarcoma market are:<\/strong>
1. Blueprint Medicines Corporation<\/span>
2. Advenchen Laboratories\/Jiangsu Chia-Tai Tianqing Pharmaceutical<\/span>
3. Karyopharm Therapeutics<\/span>
4. Deciphera Pharmaceuticals<\/span>
5. Philogen<\/span>
6. GlaxoSmithKline<\/span>
7. Epizyme<\/span>
8. Eli Lilly and Company<\/span>
9. Pfizer<\/span>
10. Aadi Bioscience<\/span>
11. Sierra Oncology<\/span>
12. Nanobiotix<\/span>
13. Taiho Oncology<\/span>
14. Arog Pharmaceuticals<\/span>
15. Merck Sharp & Dohme<\/span>
And many others<\/span><\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/soft-tissue-sarcoma-pipeline-insight<\/strong><\/a><\/p>\n

Table of contents:<\/strong><\/p>\n

\n
\n
\n

1. Report Introduction<\/span><\/p>\n

2. Soft Tissue Sarcoma <\/span><\/p>\n

2.1. Overview<\/span><\/p>\n

2.2. History <\/span><\/p>\n

2.3. Soft Tissue Sarcoma Symptoms<\/span><\/p>\n

2.4. Causes<\/span><\/p>\n

2.5.Pathophysiology<\/span><\/p>\n

2.6. Soft Tissue Sarcoma Diagnosis <\/span><\/p>\n

2.6.1. Diagnostic Guidelines<\/span><\/p>\n

3. Soft Tissue Sarcoma Current Treatment Patterns<\/span><\/p>\n

3.1. Soft Tissue Sarcoma Treatment Guidelines<\/span><\/p>\n

4. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective<\/span><\/p>\n

4.1. In-depth Commercial Assessment<\/span><\/p>\n

4.1.1. Soft Tissue Sarcoma companies collaborations, Licensing, Acquisition -Deal Value Trends<\/span><\/p>\n

4.1.1.1. Assessment Summary<\/span><\/p>\n

4.1.2. Soft Tissue Sarcoma Collaboration Deals<\/span><\/p>\n

4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n

4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n

4.1.2.3. Soft Tissue Sarcoma Acquisition Analysis<\/span><\/p>\n

5. Therapeutic Assessment<\/span><\/p>\n

5.1. Clinical Assessment of Pipeline Drugs <\/span><\/p>\n

5.1.1. Assessment by Phase of Development<\/span><\/p>\n

5.1.2. Assessment by Product Type (Mono \/ Combination)<\/span><\/p>\n

5.1.2.1. Assessment by Stage and Product Type<\/span><\/p>\n

5.1.3. Assessment by Route of Administration<\/span><\/p>\n

5.1.3.1. Assessment by Stage and Route of Administration<\/span><\/p>\n

5.1.4. Assessment by Molecule Type<\/span><\/p>\n

5.1.4.1. Assessment by Stage and Molecule Type<\/span><\/p>\n

5.1.5. Assessment by MOA<\/span><\/p>\n

5.1.5.1. Assessment by Stage and MOA<\/span><\/p>\n

5.1.6. Assessment by Target<\/span><\/p>\n

5.1.6.1. Assessment by Stage and Target<\/span><\/p>\n

6. Soft Tissue Sarcoma Late Stage Products (Phase-III)<\/span><\/p>\n

7. Soft Tissue Sarcoma Mid Stage Products (Phase-II)<\/span><\/p>\n

8. Early Stage Products (Phase-I)<\/span><\/p>\n

9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n

10. Inactive Products<\/span><\/p>\n

11. Dormant Products<\/span><\/p>\n

12. Soft Tissue Sarcoma Discontinued Products<\/span><\/p>\n

13. Soft Tissue Sarcoma Product Profiles<\/span><\/p>\n

13.1. Drug Name: Company <\/span><\/p>\n

13.1.1. Product Description<\/span><\/p>\n

13.1.1.1. Product Overview<\/span><\/p>\n

13.1.1.2. Mechanism of action<\/span><\/p>\n

13.1.2. Research and Development<\/span><\/p>\n

13.1.2.1. Clinical Studies<\/span><\/p>\n

13.1.3. Product Development Activities<\/span><\/p>\n

13.1.3.1. Collaboration<\/span><\/p>\n

13.1.3.2. Agreements<\/span><\/p>\n

13.1.3.3. Acquisition <\/span><\/p>\n

13.1.3.4. Patent Detail<\/span><\/p>\n

13.1.4. Tabulated Product Summary<\/span><\/p>\n

13.1.4.1. General Description Table<\/span><\/p>\n

Detailed information in the report? <\/span><\/p>\n

14. Soft Tissue Sarcoma Key Companies<\/span><\/p>\n

15. Soft Tissue Sarcoma Key Products<\/span><\/p>\n

16. Dormant and Discontinued Products<\/span><\/p>\n

16.1. Dormant Products<\/span><\/p>\n

16.1.1. Reasons for being dormant<\/span><\/p>\n

16.2. Discontinued Products <\/span><\/p>\n

16.2.1. Reasons for the discontinuation<\/span><\/p>\n

17. Soft Tissue Sarcoma Unmet Needs<\/span><\/p>\n

18. Soft Tissue Sarcoma Future Perspectives<\/span><\/p>\n

19. Soft Tissue Sarcoma Analyst Review  <\/span><\/p>\n

20. Appendix<\/span><\/p>\n

21. Report Methodology<\/span><\/p>\n

21.1. Secondary Research<\/span><\/p>\n

21.2. Expert Panel Validation <\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/div>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Soft Tissue Sarcoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,412,406,404],"tags":[],"class_list":["post-483180","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483180"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483180\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}